Gary P Wormser Selected Research

Erythema

7/2021	Evaluation of selected variables to determine if any had predictive value for, or correlated with, residual symptoms at approximately 12 months after diagnosis and treatment of early Lyme disease.
1/2021	Corrigendum to: Transcriptome Assessment of Erythema Migrans Skin Lesions in Patients With Early Lyme Disease Reveals Predominant Interferon Signaling.
12/2020	Patients with Erythema Migrans: Characterizing the Impact of Initiation of Antibiotic Therapy Prior to Study Enrollment.
12/2020	Prospective Evaluation of the Frequency and Severity of Symptoms in Lyme Disease Patients With Erythema Migrans Compared With Matched Controls at Baseline, 6 Months, and 12 Months.
8/2020	Evaluation of the role of oral penicillin for treating Lyme disease patients with erythema migrans in the United States.
1/2020	Measurement of Organ-Specific and Acute-Phase Blood Protein Levels in Early Lyme Disease.
11/2019	Is Doxycycline Appropriate for Routine Treatment of Young Children With Erythema Migrans?
9/2019	A 14-day course of amoxicillin is a highly effective treatment for adult patients in the United States with erythema migrans.
6/2019	Efficacy of a 14-day course of amoxicillin for patients with erythema migrans.
1/2019	Evaluation of Prospectively Followed Adult Patients with Erythema Migrans Using the Beck Depression Inventory Second Edition.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gary P Wormser Research Topics

Disease

82	Lyme Disease (Disease, Lyme) 01/2022 - 01/2002
30	Infections 01/2022 - 06/2005
28	Erythema 07/2021 - 07/2002
9	Tick Bites 01/2022 - 06/2005
9	Post-Lyme Disease Syndrome 10/2021 - 06/2009
8	Babesiosis (Piroplasmosis) 01/2022 - 02/2008
7	Fatigue 01/2018 - 07/2009
6	Communicable Diseases (Infectious Diseases) 01/2022 - 07/2005
4	Syphilis 04/2021 - 01/2020
4	Pain (Aches) 02/2013 - 08/2010
3	Relapsing Fever 04/2021 - 09/2016
3	Malaria 01/2019 - 02/2008
2	Facial Paralysis (Facial Palsy) 08/2018 - 08/2018
2	Meningitis 08/2018 - 05/2003
2	Thrombocytopenia (Thrombopenia) 02/2018 - 03/2013
2	Headache (Headaches) 01/2018 - 03/2013
2	Myocarditis (Carditis) 01/2017 - 01/2010
2	Acquired Immunodeficiency Syndrome (AIDS) 09/2011 - 05/2011
2	Arthritis (Polyarthritis) 01/2010 - 10/2002
2	Ehrlichiosis 06/2005 - 07/2002
1	Lymphadenopathy 04/2021
1	COVID-19 12/2020
1	Lyme Neuroborreliosis 09/2020
1	Convalescence 01/2020
1	Zika Virus Infection 09/2019
1	Radiculopathy (Radiculopathy, Cervical) 08/2018
1	Bell Palsy (Bell's Palsy) 08/2018
1	Paralysis (Palsy) 08/2018
1	Anemia 02/2018
1	Neutropenia 02/2018
1	Tick-Borne Encephalitis (Encephalitis, Tick Borne) 01/2018
1	Arthralgia (Joint Pain) 01/2018
1	Coinfection 01/2018
1	Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) 01/2018
1	Myalgia 01/2018
1	Acute-Phase Reaction 12/2016
1	Rheumatoid Arthritis 06/2016

Drug/Important Bio-Agent (IBA)

37	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 01/2002
16	Doxycycline (Periostat)FDA LinkGeneric 01/2022 - 05/2003
14	AntibodiesIBA 09/2021 - 01/2002
10	EnzymesIBA 01/2022 - 04/2003
9	Peptides (Polypeptides)IBA 01/2022 - 10/2002
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2013
8	Immunoglobulin G (IgG)IBA 01/2020 - 04/2003
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2005
6	Azithromycin (Zithromax)FDA LinkGeneric 01/2022 - 02/2008
6	Immunoglobulin M (IgM)IBA 09/2021 - 04/2003
6	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 08/2018 - 01/2002
5	AntigensIBA 01/2020 - 10/2002
5	ImmunosorbentsIBA 01/2018 - 04/2003
5	1-oleoyl-2-stearoylphosphatidylcholineIBA 01/2013 - 05/2008
4	Atovaquone (Mepron)FDA Link 01/2022 - 02/2008
4	VaccinesIBA 01/2022 - 09/2011
4	Amoxicillin (Wymox)FDA LinkGeneric 09/2019 - 04/2016
4	CytokinesIBA 01/2017 - 10/2002
4	EpitopesIBA 02/2016 - 07/2005
3	InterferonsIBA 01/2021 - 12/2017
3	cefuroxime axetil (Ceftin)FDA LinkGeneric 05/2019 - 01/2010
3	Quinine (Quinson)FDA Link 04/2016 - 02/2008
3	Clindamycin (Cleocin)FDA LinkGeneric 04/2016 - 02/2008
2	OspA proteinIBA 01/2022 - 06/2005
2	tafenoquineIBA 01/2022 - 01/2019
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2020 - 01/2018
2	Pharmaceutical PreparationsIBA 01/2019 - 02/2010
2	C-Reactive ProteinIBA 01/2018 - 12/2016
2	Rituximab (Mabthera)FDA Link 06/2016 - 02/2008
2	Ribosomal DNA (rDNA)IBA 10/2008 - 09/2002
2	OspC proteinIBA 10/2008 - 05/2008
1	Penicillins (Penicillin)FDA Link 08/2020
1	Glycerophospholipids (Phosphoglycerides)IBA 01/2020
1	acylcarnitineIBA 01/2020
1	Blood Proteins (Serum Proteins)IBA 01/2020
1	Bile Acids and Salts (Bile Acids)IBA 01/2020
1	EicosanoidsIBA 01/2020
1	SphingolipidsIBA 01/2020
1	Ivermectin (Mectizan)FDA Link 09/2019
1	Anti-Infective Agents (Microbicides)IBA 05/2019
1	Vancomycin FDA LinkGeneric 05/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2018
1	ORALIT (ORS)IBA 01/2018
1	Antiviral Agents (Antivirals)IBA 01/2018
1	Rifampin (Rifampicin)FDA LinkGeneric 11/2017
1	Fatty Acids (Saturated Fatty Acids)IBA 08/2017
1	AmidesIBA 08/2017
1	Ethanolamine (Colamine)IBA 08/2017
1	Serum Amyloid A Protein (Serum Amyloid A)IBA 12/2016
1	A 7 (A-7)IBA 04/2016
1	Borrelia burgdorferi VlsE proteinIBA 02/2016
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 02/2016
1	AutoantigensIBA 12/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2015

Therapy/Procedure

24	Therapeutics 01/2021 - 01/2002
3	Aftercare (After-Treatment) 01/2020 - 01/2010
3	Blood Transfusion (Blood Transfusions) 08/2012 - 03/2011
2	Antibiotic Prophylaxis 01/2018 - 06/2010
2	Drug Therapy (Chemotherapy) 06/2016 - 02/2010
2	Splenectomy 05/2011 - 03/2011
2	Duration of Therapy 06/2005 - 07/2002
1	Urinary Catheters 01/2022
1	Erythrocyte Transfusion 02/2018